The leucine (7)-to-proline (7) polymorphism in the signal peptide of neuropeptide Y is not associated with Alzheimer's disease or the link apolipoprotein E

Neuroscience Letters

Volumn 287, Issue 1, 2000, Pages 25-28

  Helisalmi, Seppo ^a   Valve, Raisa ^a   Karvonen, Matti K ^b   Hiltunen, Mikko ^a   Pirskanen, Mia ^a   Mannermaa, Arto ^a   Koulu, Markku ^b   Pesonen, Ullamari ^b   Uusitupa, Matti ^a   Soininen, Hilkka ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Alzheimer's disease; Apolipoprotein E; Neuropeptide Y

Indexed keywords

APOLIPOPROTEIN E; LEUCINE; NEUROPEPTIDE Y; PROLINE DERIVATIVE; SIGNAL PEPTIDE;

AGED; ALLELE; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; FINLAND; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; LEUCINE; MALE; NEUROPEPTIDE Y; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLINE; PROTEIN SORTING SIGNALS;

EID: 0034674375     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)01126-5     Document Type: Article

References (20)

1. Heilig M., Sjogren M., Blennow K., Ekman R., Wallin A. Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia. Biol. Psychiatry. 38:1995;210-216.
2. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J. Lipid Res. 31:1990;545-548.
3. Karvonen M.K., Pesonen U., Koulu M., Niskanen L., Laakso M., Rissanen A., Dekker J.M., Hart L.M., Valve R., Uusitupa M.I.J. Association of a leucine (7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat. Med. 4:1998;1434-1437.
4. Koide S., Onishi H., Hashimoto H., Kai T., Yamagami S. Plasma neuropeptide Y is reduced in patients with Alzheimer's disease. Neurosci. Lett. 198:1995;149-151.
5. Laakso M., Kesäniemi A., Kervinen K., Jauhiainen M., Pyörälä K. Relation of coronary heart disease and apolipoprotein E phenotype in patients with non-insulin-dependent diabetes. Br. Med. J. 303:1991;1159-1162.
6. Lehtovirta M., Soininen H., Helisalmi S., Mannermaa A., Helkala E.-L., Hartikainen P., Hänninen T., Ryynänen M., Riekkinen P. Sr. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology. 46:1996;413-419.
7. Mahley R.W., Angelin B. Type III hyperlipoproteinemia: recent insights into genetic defect of familial dysbetalipoproteinemia. Adv. Intern. Med. 29:1984;385-411.
8. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
9. Menzel H.J., Kladentzky R.G., Assmann G. Apolipoprotein E polymorphism and coronary heart disease. Atherosclerosis. 3:1983;310-315.
10. Minthon L., Edvinsson L., Gustafson L. Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. Dement. Geriatr. Cogn. Disord. 8:1997;232-239.
11. Palmiter R.D., Erickson J.C., Hollopeter G., Baraban S.C., Schwartz M.W. Life without neuropeptide Y. Recent Prog. Horm. Res. 53:1998;163-169.
12. Payami H., Zareparsi S., Montee K.R., Sexton G.J., Kaye J.A., Bird T.D., Yu C.E., Wijsman E.M., Heston L.L., Litt M., Schellenberg G.D. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am. J. Hum. Genet. 58:1996;803-811.
13. Rudrasingham V., Wavrant-DeVrièze F., Lambert J.-C., Chakraverty S., Kehoe P., Crook R., Amouyel P., Wu W., Rice F., Perez-Tur J., Frigard B., Morris J.C., Carty S., Petersen R., Cottel D., Tunstal N., Holmans P., Lovestone S., Chartier-Harlin M.-C., Goate A., Hardy J., Owen M.J., Williams J. α-2 Macroglobulin gene and Alzheimer disease. Nat. Genet. 22:1999;17-19.
14. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B., Gusella J.F., Crapper-MacLahian D.R., Alberts M.J., Hulette C., Crain B., Goidgaber D., Roses A.D. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
15. Schächter F., Faure-Delanef L., Gue'not F., Rouger H., Froguel P., Lesueur-Ginot L., Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat. Genet. 6:1994;29-32.
16. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Engild J., Salvesen G., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. 121:1993;1977-1981.
17. Tanzi R. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. J. Clin. Invest. 104:1999;1175-1179.
18. Uusitupa M.I.J., Karvonen M.K., Pesonen U., Koulu M. Neuropeptide Y: a novel link between the neuroendocrine system and cholesterol metabolism. Ann. Med. 30:1998;508-510.
19. Vandenplas S., Grobler-Rabie A., Brebner K., Rickets M., Wallis G., Bester A., Boyd C., Mathew C. Blot hybridization of genomic DNA. J. Med. Genet. 21:1984;164-172.
20. Weisgraber K.H., Mahley R.W. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 10:1996;1485-1494.